Clinical Trials for Other Solid Tumor

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with metastatic, pMMR/MSS colorectal adenocarcinoma (no liver or CNS metastases, ECOG 0-1, no prior systemic therapy for metastatic disease) to evaluate the addition of volrustomig—a bispecific anti-PD-1/CTLA-4 antibody—to FOLFIRI and bevacizumab versus standard FOLFIRI plus bevacizumab. Volrustomig is designed to enhance immune response by targeting CTLA-4 selectively on PD-1+ T cells.

ClinicalTrials.gov ID: NCT06792695

A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab and to Evaluate Safety and Efficacy of ABBV-400 in Combination With Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with unresectable metastatic colorectal cancer who have progressed after one prior systemic therapy (excluding those with BRAF V600E mutations or dMMR/MSI-H tumors) to evaluate ABBV-400, a c-Met–targeting antibody-drug conjugate delivering a topoisomerase 1 inhibitor, in combination with fluorouracil, folinic acid, and bevacizumab, compared to standard second-line therapy.

ClinicalTrials.gov ID: NCT06107413

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with unresectable or metastatic, anti-EGFR-refractory, KRAS/NRAS/BRAF V600E/EGFR WT advanced colorectal cancer (progressed on EGFR antibody and standard chemotherapy), and treats them with avutometinib (a dual RAF/MEK inhibitor), defactinib (FAK inhibitor), and cetuximab. Prior BRAF/MEK/ERK inhibitor therapy and active CNS metastases are exclusion criteria.

ClinicalTrials.gov ID: NCT06369259

A Phase II Study of Immunotherapies (Tiragolumab and Atezolizumab) in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with microsatellite stable metastatic colorectal cancer who have progressed after at least two prior therapies and have at least two lesions, testing combination therapy with atezolizumab (anti-PD-L1), tiragolumab (anti-TIGIT), and stereotactic body radiation therapy. Patients must be immunotherapy-naïve and fit (ECOG 0-1), with one lesion suitable for SBRT and another measurable for response.

ClinicalTrials.gov ID: NCT06603818

A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with metastatic colorectal cancer (ECOG 0-1) and tests combinations of telisotuzumab adizutecan, a c-Met–targeting antibody-drug conjugate linked to a topoisomerase I inhibitor, with standard regimens (FOLFOX plus bevacizumab or 5-FU/LV plus panitumumab) versus standard therapy alone, excluding patients with prior c-Met or topoisomerase inhibitor treatment.

ClinicalTrials.gov ID: NCT06820463

Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with newly diagnosed, metastatic or unresectable, microsatellite stable colorectal cancer (no liver, bone, or brain metastases, ECOG 0-1, and no prior systemic therapy for metastatic disease), testing combination immunotherapy with botensilimab (Fc-enhanced anti-CTLA-4) and balstilimab (PD-1 inhibitor), with mFOLFOX6 plus bevacizumab or panitumumab added if disease progresses.

ClinicalTrials.gov ID: NCT06268015

An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial assesses the safety and efficacy of naporafenib, a pan-RAF kinase inhibitor, combined with trametinib, a MEK inhibitor, in patients aged 12 and older with previously treated, RAS Q61X-mutated locally advanced unresectable or metastatic solid tumors lacking standard treatment options. Patients with neurologically unstable primary CNS tumors or CNS metastases are excluded.

ClinicalTrials.gov ID: NCT05907304

A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial compares the combination of pembrolizumab and valemetostat tosylate, a dual EZH1/2 inhibitor, with pembrolizumab alone in patients with advanced or metastatic non-small cell lung cancer expressing PD-L1 ≥50% and lacking actionable genomic alterations. It includes patients who have not received prior systemic therapy and have a performance status of 0 or 1.

ClinicalTrials.gov ID: NCT06644768

The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial evaluates NC318, a Siglec-15-targeting monoclonal antibody, alone or with pembrolizumab in patients with advanced non-small cell lung cancer who have progressed following PD-1 inhibitor therapy or are PD-1 inhibitor naïve. It includes multiple treatment arms based on prior treatments and tumor PD-L1 expression levels.

ClinicalTrials.gov ID: NCT04699123

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with recurrent metastatic breast cancer of any subtype who have progressed after all standard therapies, including those with stable brain metastases, to receive an HLA-matched, off-the-shelf allogeneic cellular immunotherapy (Bria-OTS, designed to induce anti-tumor immune responses), given alone or in combination with cyclophosphamide, peginterferon alpha-2a, and the PD-1 inhibitor tislelizumab.

ClinicalTrials.gov ID: NCT06471673